THROMBOPOIETIN RECEPTOR AGONIST ELTROMBOPAG FOR ADVANCED MDS OR AML AND SEVERE THROMBOCYTOPENIA: 12-WEEK, RANDOMIZED, PLACEBO-CONTROLLED, PHASE 2 ASPIRE STUDY

被引：0
|
作者：
Mittelman, M. [1 ]
Platzbecker, U. [2 ]
Afanasyev, B. [3 ]
Grosicki, S. [4 ]
Wong, R. S. [5 ,6 ]
Anagnostopoulos, A. [7 ]
Brenner, B. [8 ]
Denzlinger, C. [9 ]
Rossi, G. [10 ]
Nagler, A. [11 ]
Garcia Delgado, R. [12 ]
Stone, N. [13 ]
Zhu, Z. [13 ]
Kalambakas, S. [13 ]
Selleslag, D. [14 ]
机构：
[1] Tel Aviv Univ, Tel Aviv Sourasky Med Ctr, Tel Aviv, Israel
[2] Univ Klinikum Carl Gustav Carus, Dresden, Germany
[3] Pavlov State Med Univ, St Petersburg, Russia
[4] Silesian Med Univ, Katowice, Poland
[5] Chinese Univ Hong Kong, Sir YK Pao Ctr Canc, Shatin, Hong Kong, Peoples R China
[6] Chinese Univ Hong Kong, Dept Med & Therapeut, Shatin, Hong Kong, Peoples R China
[7] G Papanikolaou Gen Hosp, Thessaloniki, Greece
[8] Rambam Med Ctr, Haifa, Israel
[9] Marienhosp Stuttgart, Stuttgart, Germany
[10] Azienda Osped Spedali Civili, Brescia, Italy
[11] Chaim Sheba Med Ctr, Ramat Gan, Israel
[12] Hosp Virgen de la Victoria, Malaga, Spain
[13] Novartis Pharmaceut, E Hanover, NJ USA
[14] AZ St Jan Brugge AV, Brugge, Belgium
来源：
HAEMATOLOGICA | 2016年 / 101卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
S130
引用
收藏
页码：15 / 16
页数：2
相关论文
共 50 条
  • [21] A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 12-WEEK STUDY OF ENCENICLINE OR PLACEBO IN SCHIZOPHRENIA SUBJECTS ON CHRONIC STABLE ATYPICAL ANTIPSYCHOTIC THERAPY
    Lombardo, I.
    Dgetluck, N.
    Hilt, D.
    Koenig, G.
    Loewen, G.
    SCHIZOPHRENIA BULLETIN, 2015, 41 : S321 - S322
  • [22] Dupilumab significantly improves sleep in adults with atopic dermatitis: results from the 12-week placebo-controlled period of the 24-week phase IV randomized double-blinded placebo-controlled DUPISTAD study
    Merola, Joseph F.
    Chiou, Albert S.
    During, Emmanuel
    Costanzo, Antonio
    Foley, Peter
    Alfalasi, Amani
    Gogate, Shaila
    Pinter, Andreas
    Dodiuk-Gad, Roni
    Simon, Dagmar
    Tauber, Marie
    Weller, Richard
    Pereyra-Rodriguez, Jose-Juan
    Ardeleanu, Marius
    Wu, Jiangming
    Ozturk, Zafer E.
    BRITISH JOURNAL OF DERMATOLOGY, 2023, 189 (06) : 685 - 694
  • [23] Effect of deutetrabenazine on QTcF interval in the AIM-TD study: A 12-week, phase III, randomized, double-blind, placebo-controlled study
    Anderson, K.
    Stamler, D.
    Davis, M.
    Factor, S.
    Hauser, R.
    Isojarvi, J.
    Jarskog, L.
    Jimenez-Shahed, J.
    Kumar, R.
    Ochudlo, S.
    Ondo, W.
    Fernandez, H.
    MOVEMENT DISORDERS, 2017, 32
  • [24] Efficacy and safety of canagliflozin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, 12-week study
    Inagaki, N.
    Kondo, K.
    Yoshinari, T.
    Maruyama, N.
    Susuta, Y.
    Kuki, H.
    DIABETES OBESITY & METABOLISM, 2013, 15 (12): : 1136 - 1145
  • [25] Pancreatic Effects of Liraglutide or Sitagliptin in Overweight Patients With Type 2 Diabetes: A 12-Week Randomized, Placebo-Controlled Trial
    Smits, Mark M.
    Tonneijck, Lennart
    Muskiet, Marcel H. A.
    Kramer, Mark H. H.
    Pieters-van den Bos, Indra C.
    Vendrik, Karuna E. W.
    Hoekstra, Trynke
    Bruno, Marco J.
    Diamant, Michaela
    van Raalte, Daniel H.
    Cahen, Djuna L.
    DIABETES CARE, 2017, 40 (03) : 301 - 308
  • [26] Efficacy and tolerability of valdecoxib in treating the signs and symptoms of severe rheumatoid arthritis: A 12-week, multicenter, randomized, double-blind, placebo-controlled study
    Gibofsky, Allan
    Rodrigues, Jude
    Fiechtner, Justus
    Berger, Manuela
    Pan, Sharon
    CLINICAL THERAPEUTICS, 2007, 29 (06) : 1071 - 1085
  • [27] ORAL THROMBOPOIETIN RECEPTOR AGONIST ELTROMBOPAG TREATMENT DURING INDUCTION CHEMOTHERAPY FOR ACUTE MYELOGENOUS LEUKEMIA (AML): RESULTS OF A RANDOMIZED, DOUBLE-BLIND, PHASE 2 STUDY
    Frey, N.
    Strickland, S.
    Szer, J.
    Illes, A.
    Kim, H. J.
    Ram, R.
    Chong, B.
    Rowe, J. M.
    Borisenkova, E.
    Liesveld, J.
    Winer, E.
    Cherfi, A.
    Kalambakas, S.
    Jang, J. H.
    HAEMATOLOGICA, 2016, 101 : 40 - 41
  • [28] Tildrakizumab for moderate-to-severe plaque psoriasis in Chinese patients: A 12-week randomized placebo-controlled phase III trial with long-term extension
    Yu Chen
    Geng Songmei
    Yang Bin
    Deng Yunhua
    Li Fuqiu
    Kang Xiaojing
    Bi Mingye
    Zhang Furen
    Zhao Yi
    Pan Weili
    Tian Zhongwei
    Xu Jinhua
    Zhang Zhenghua
    Yu Nan
    Duan Xinsuo
    Guo Shuping
    Sun Qing
    Li Weiquan
    Tao Juan
    Liu Zhijun
    Yin Yuanyuan
    Wang Gang
    中华医学杂志英文版, 2024, 137 (10)
  • [29] Tildrakizumab for moderate-to-severe plaque psoriasis in Chinese patients: A 12-week randomized placebo-controlled phase III trial with long-term extension
    Yu, Chen
    Geng, Songmei
    Yang, Bin
    Deng, Yunhua
    Li, Fuqiu
    Kang, Xiaojing
    Bi, Mingye
    Zhang, Furen
    Zhao, Yi
    Pan, Weili
    Tian, Zhongwei
    Xu, Jinhua
    Zhang, Zhenghua
    Yu, Nan
    Duan, Xinsuo
    Guo, Shuping
    Sun, Qing
    Li, Weiquan
    Tao, Juan
    Liu, Zhijun
    Yin, Yuanyuan
    Wang, Gang
    CHINESE MEDICAL JOURNAL, 2024, 137 (10) : 1190 - 1198
  • [30] Comment on 'Dupilumab significantly improves sleep in adults with atopic dermatitis: results from the 12-week placebo-controlled period of the 24-week phase IV randomized double-blinded placebo-controlled DUPISTAD study'
    Johnson, Chandler
    Smith, Payton
    Haran, Kathryn
    Kranyak, Allison
    Liao, Wilson
    Bhutani, Tina
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 190 (04) : 596 - 596
12345